Linda Rubinstein
Finanzdirektor/CFO bei ADVERUM BIOTECHNOLOGIES, INC.
Vermögen: 93 900 $ am 31.01.2024
Profil
Linda M.
Rubinstein is currently a Partner at FLG Partners LLC since 2010 and the Chief Financial & Accounting Officer at Adverum Biotechnologies, Inc. since 2022.
Previously, she served as an Independent Director at Biocept, Inc. from 2021 to 2023 and as a Director at Sensor Innovations, Inc. from 2007 to 2015.
Linda also held positions at Lehman Brothers, Inc., Five Prime Therapeutics, Inc., Ingenuity Systems, Inc., Emergent Travel Health, Inc., RenovoRx, Inc., Merrill Lynch Capital Partners, Inc., Solexa, Inc., and iPierian, Inc. She was the Chief Financial Officer at Solexa, Inc. from 2005 to 2007 and the Chief Financial Officer at ArmaGen, Inc. from 2015 to 2020.
Linda's education includes undergraduate and graduate degrees from the University of California, Los Angeles.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 22.04.2024 | 10 000 ( 0,05% ) | 93 900 $ | 30.04.2024 | |
BIOCEPT, INC.
-.--% | 28.02.2023 | 0 ( -.--% ) | - $ | 31.01.2024 |
Aktive Positionen von Linda Rubinstein
| Unternehmen | Position | Beginn |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Finanzdirektor/CFO | 12.12.2022 |
FLG Partners LLC
 FLG Partners LLC Miscellaneous Commercial ServicesCommercial Services FLG Partners LLC is a CFO solutions, CEO, and board advisory services provider based in Silicon Valley. The private company is based in Palo Alto, CA, and has subsidiaries in the United States. The company offers financial and operational leadership to a wide range of companies, from newly funded startups to Fortune 100 companies, across various sectors, including technology, life sciences, and consumer products. The firm's partners engage clients in interim or long-term assignments in leadership roles that typically are consulting engagements. FLG Partners has helped raise over $6 billion in growth financing, IPO, and M&A transactions for the firm's clients since January 2021. The company was founded by Douglas J. Lehrmann, Jeffrey S. Kuhn, Kyle W. Smith. | Corporate Officer/Principal | 01.09.2010 |
Ehemalige bekannte Positionen von Linda Rubinstein
| Unternehmen | Position | Ende |
|---|---|---|
| BIOCEPT, INC. | Direktor/Vorstandsmitglied | 13.10.2023 |
| APEXIGEN, INC. | Finanzdirektor/CFO | 10.06.2022 |
| ALECTOR, INC. | Finanzdirektor/CFO | 07.02.2022 |
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Finanzdirektor/CFO | 01.04.2020 |
| FIVE PRIME THERAPEUTICS, INC. | Finanzdirektor/CFO | 26.11.2018 |
Ausbildung von Linda Rubinstein
| University of California, Los Angeles | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| BIOCEPT, INC. | Health Technology |
| RENOVORX, INC. | Health Technology |
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| ALECTOR, INC. | Health Technology |
| APEXIGEN, INC. | Health Technology |
| Private Unternehmen | 10 |
|---|---|
Lehman Brothers, Inc.
 Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | Finance |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
Ingenuity Systems, Inc.
 Ingenuity Systems, Inc. Information Technology ServicesTechnology Services Ingenuity Systems, Inc. provides intuitive web-based applications for quickly analyzing and accurately interpreting the biological meaning of genomics data. The company was founded in 1998 and is headquartered in Redwood City, CA. | Technology Services |
Emergent Travel Health, Inc.
 Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | Technology Services |
Sensor Innovations, Inc.
 Sensor Innovations, Inc. BiotechnologyHealth Technology Sensor Innovations, Inc. develops and commercializes a novel, proprietary and versatile sensing technology platform. It is initially focusing on pH measurement in high-value manufacturing, where an internally referenced, continuously self-calibrating sensor without drift is advantageous. The company was founded by Carolyn R. Kahn in 2007 and is headquartered in Burlingame, CA. | Health Technology |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
Merrill Lynch Capital Partners, Inc.
 Merrill Lynch Capital Partners, Inc. Investment Banks/BrokersFinance Part of Bank of America Corp., Merrill Lynch Capital Partners, Inc. is a security broker and dealer. The company is based in New York, NY. The company was founded by Jim J. Burke. | Finance |
Solexa, Inc.
 Solexa, Inc. Pharmaceuticals: OtherHealth Technology Solexa, Inc. used to create DNA cloning and analyses technologies to enhance gene discovery. It also used to provide genomics, genetics and proteomics technologies to assist the customers in the field of pharmaceutical and agriculture. The company was located in Hayward, CA. | Health Technology |
iPierian, Inc.
 iPierian, Inc. Pharmaceuticals: MajorHealth Technology ierian, Inc. developed and manufactured biopharmaceutical products. The firm's lead antibody, IPN007, represents a new approach to treating neurodegenerative disease by targeting a novel form of secreted Tau protein. The company was founded in 2007 and is headquartered in South San Francisco, CA. | Health Technology |
FLG Partners LLC
FLG Partners LLC Miscellaneous Commercial ServicesCommercial Services FLG Partners LLC is a CFO solutions, CEO, and board advisory services provider based in Silicon Valley. The private company is based in Palo Alto, CA, and has subsidiaries in the United States. The company offers financial and operational leadership to a wide range of companies, from newly funded startups to Fortune 100 companies, across various sectors, including technology, life sciences, and consumer products. The firm's partners engage clients in interim or long-term assignments in leadership roles that typically are consulting engagements. FLG Partners has helped raise over $6 billion in growth financing, IPO, and M&A transactions for the firm's clients since January 2021. The company was founded by Douglas J. Lehrmann, Jeffrey S. Kuhn, Kyle W. Smith. | Commercial Services |
